By Dr. James W. Stark

The FDA has approved Plegridy, which is a pegylated (long-acting) formulation of Avonex. Plegridy is administered every other week, subcutaneously (instead of intramuscularly) but is otherwise similar to Avonex in terms of efficacy and side effect profile. This medication should become available to patients soon. If you would like to learn more, please bring it up with your physician at your next office visit.